Description:Irisin can ameliorate postmenopausal osteoporosis (PMOP) in ovariectomized (OVX) mice by promoting osteogenesis, inhibiting adipogenesis, and regulating the bone-fat balance. Similarly, irisin enhances the osteogenic differentiation of human bone marrow mesenchymal stem cells (BMSCs) in vitro while reducing their adipogenic differentiation. Metabolomic analysis of mouse plasma revealed that the therapeutic effects of irisin are associated with pathways such as glycerophospholipid metabolism, wherein the metabolite phosphatidylcholine (PC) plays a significant role. Irisin can upregulate the metabolism of PC in OVX mice, thereby improving OP. We further investigated the metabolic role of PC and its mechanisms. By administering PC to BMSCs, we observed its effects on BMSCs and the underlying mechanisms. It was found that PC activates the canonical Wnt/β-catenin signaling pathway, promoting the osteogenic differentiation of BMSCs while inhibiting their adipogenic differentiation.